

Keli L Hippen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6247795/publications.pdf>

Version: 2024-02-01

34
papers

2,382
citations

331670

21
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

4163
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T ^H cells and hematopoietic stem and progenitor cells using base editing. <i>Molecular Therapy</i> , 2022, 30, 130-144.	8.2	23
2	Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. <i>Cell Reports</i> , 2022, 39, 110727.	6.4	1
3	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	12.8	18
4	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
5	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	1.4	8
6	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436.	5.2	39
7	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. <i>Cytotherapy</i> , 2021, 23, 704-714.	0.7	7
8	Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. <i>Cell Metabolism</i> , 2020, 31, 422-437.e5.	16.2	215
9	Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. <i>Trends in Immunology</i> , 2020, 41, 77-91.	6.8	31
10	ICOSL ⁺ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	15
11	Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration. <i>Cell Reports</i> , 2020, 30, 1052-1062.e5.	6.4	27
12	The lymph node stromal laminin $\alpha 5$ shapes alloimmunity. <i>Journal of Clinical Investigation</i> , 2020, 130, 2602-2619.	8.2	21
13	The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. <i>Nature Communications</i> , 2019, 10, 354.	12.8	74
14	CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. <i>Science Immunology</i> , 2019, 4, .	11.9	70
15	Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol. <i>Cytotherapy</i> , 2019, 21, 1216-1233.	0.7	18
16	Rorc restrains the potency of ST2 ⁺ regulatory T cells in ameliorating intestinal graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	5.0	18
17	miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). <i>Cell Death and Disease</i> , 2018, 9, 290.	6.3	37
18	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	12.8	45

#	ARTICLE	IF	CITATIONS
19	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. <i>Cancer Immunology Research</i> , 2018, 6, 766-775.	3.4	75
20	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 57.	4.8	46
21	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4604-4621.	8.2	32
22	Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions. <i>Cellular and Molecular Immunology</i> , 2017, 14, 521-528.	10.5	147
23	A robust in vitro model for trans-lymphatic endothelial migration. <i>Scientific Reports</i> , 2017, 7, 1633.	3.3	27
24	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. <i>Translational Research</i> , 2017, 179, 116-125.	5.0	16
25	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.7	41
26	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	1.4	333
27	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016, 128, 1424-1435.	1.4	70
28	Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. <i>Nature Communications</i> , 2016, 7, 12021.	12.8	54
29	Preclinical Testing of Antihuman CD28 Fab Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. <i>Transplantation</i> , 2016, 100, 2630-2639.	1.0	13
30	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. <i>Molecular Therapy</i> , 2016, 24, 570-581.	8.2	168
31	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16814-16819.	7.1	185
32	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. <i>Blood</i> , 2012, 119, 619-628.	1.4	79
33	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	12.4	326
34	Clinical perspectives for regulatory T cells in transplantation tolerance. <i>Seminars in Immunology</i> , 2011, 23, 462-468.	5.6	95